# C_2011145EN.01000201.xml

| 14.5.2011 | EN | Official Journal of the European Union | C 145/2 |
| --------- | -- | -------------------------------------- | ------- |

---

Judgment of the Court (Fourth Chamber) of 22 December 2010 — European Commission v Republic of Poland

(Case C-385/08)( 1 )

(Failure of a Member State to fulfil obligations - Accession of new Member States - Marketing authorisations for medicinal products that are generics of the reference product Plavix - Conditional decisions authorising the marketing of pharmaceutical products - Infringement of the acquis)

2011/C 145/02

Language of the case: Polish

Parties

Applicant: European Commission (represented by: M. Šimerdová and K. Herrmann, agents, acting as Agents

Defendant: Republic of Poland (represented by: M. Dowgielewicz and B. Majczyna, agents)

Intervener in support of the defendant: Republic of Lithuania (represented by: D. Kriaučiūnas and R. Mackevičienė, agents)

Re:

Failure of a Member State to fulfil obligations — Infringement of Article 6(1) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), read in conjunction with Article 13(4) of Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products (OJ 1993 L 214, p. 1) and with Articles 89 and 90 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1) — Marketing authorisations for medicinal products that are generics of the reference product Plavix, in breach of the 10-year period of protection enjoyed by the latter — Conditional decisions authorising the marketing of pharmaceutical products, issued before the date of Poland’s accession to the European Union but not becoming effective until after that date — Decisions inconsistent with the provisions of Directive 2001/83/EC

Operative part of the judgment

The Court:

| 1. | Declares that,
—
by retaining in force the decisions of the Minister for Health concerning marketing authorisations for medicinal products that are generics of the reference product Plavix, and —
by placing and keeping on the market, after 1 May 2004, medicinal products whose marketing authorisation was not issued in accordance with Article 6(1) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, the Republic of Poland has failed to fulfil its obligations, as regards the first indent above, under Article 6(1) of Directive 2001/83, in conjunction with Article 13(4) of Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products and with Articles 89 and 90 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency and, as regards the second indent above, under Article 6(1) of Directive 2001/83. | — | by retaining in force the decisions of the Minister for Health concerning marketing authorisations for medicinal products that are generics of the reference product Plavix, and | — | by placing and keeping on the market, after 1 May 2004, medicinal products whose marketing authorisation was not issued in accordance with Article 6(1) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, |
| -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | - | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | - | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| — | by retaining in force the decisions of the Minister for Health concerning marketing authorisations for medicinal products that are generics of the reference product Plavix, and | | | | |
| — | by placing and keeping on the market, after 1 May 2004, medicinal products whose marketing authorisation was not issued in accordance with Article 6(1) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, | | | | |

| 2. | Orders the Republic of Poland to pay the costs. |
| -- | ----------------------------------------------- |

| 3. | Orders the Republic of Lithuania to bear its own costs. |
| -- | ------------------------------------------------------- |

---

( 1 )  OJ C 313, 6.12.2008.

---